Biotechs Show Off Early-Stage Progress At AACR Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Novel platforms presented at American Association for Cancer Research annual meeting generate workarounds for the blood-brain barrier (AngioChem), drug resistance (Avila) and tumor mutations (Micromet).
You may also be interested in...
Novartis Options Avila's Protein-Silencing
Deal signals growing role for corporate VC and acceptance of option structure .
Novartis Options Avila's Protein-Silencing
Deal signals growing role for corporate VC and acceptance of option structure .
Navigating The Blood-Brain Barrier: An Interview With AngioChem CEO Jean-Paul Castaigne
Castaigne talks about combining AngioChem’s proprietary technology with cytotoxins, mAbs, siRNA and peptides to create therapies for cancer and neurodegenerative diseases and, oh yes, to solve the obesity problem.